WEIGAO GROUP's revenue in the third quarter was approximately 3.26 billion yuan, a year-on-year increase of about 2.6%
According to the announcement from WEIGAO GROUP, for the three months ending September 30, 2025, the company achieved unaudited revenue of approximately RMB 3.26 billion, an increase of about 2.6% compared to the same period last year. Among them, the orthopedics, interventional, and blood management segments experienced rapid revenue growth; however, the pharmaceutical packaging and general medical device segments were impacted by policy-related pressure on the sales prices of products such as syringe injectors, which dragged down the overall sales revenue growth of the group
According to the announcement from WEIGAO GROUP (01066), for the three months ending September 30, 2025, the company achieved unaudited revenue of approximately RMB 3.26 billion, an increase of about 2.6% compared to the same period last year. Among them, the orthopedics, interventional, and blood management segments experienced rapid revenue growth; however, the pharmaceutical packaging and general medical device segments were impacted by continued pressure on sales prices of products such as syringe injectors due to policy influences, which somewhat hindered the overall sales revenue growth of the group
